Related Experiment Video
Updated: Mar 21, 2026
Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
Published on: November 17, 2018
Antibiotic Use During Gastrointestinal Infections Increases the Risk of Developing Irritable Bowel Syndrome: A
Luigi Colecchia1,2, Giovanni Marasco1,2, Cecilia Capelli1,2
1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Introduction:
Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction which negatively affects patients' quality of life. It has been hypothesized that changes in gut microbiota composition and function evoked by antibiotic use represent a trigger for IBS development. This systematic review and meta-analysis aimed to assess the incidence of IBS after antibiotic use.
Methods:
Medline, Embase, and Scopus, along with relevant conference abstracts and citation tracking were searched up to June 15th, 2025. Studies that reported new diagnoses of IBS in patients with documented antibiotic exposure vs controls without antibiotic exposure were included. Data extraction and quality assessment were performed independently by 2 reviewers. Pooled incidence rates per 1,000 person-years, along with incidence rate ratios (IRRs) with 95% confidence intervals (CI) were pooled; heterogeneity was expressed as I2 . Metaregression analysis was performed to assess the impact of confounding covariates.
Results:
Thirty-one studies comprising a total of 422,350 patients (244,632 antibiotic users and 177,718 nonusers) were included. The overall pooled incidence of IBS was 26% in antibiotic users compared with 20% in nonusers, resulting in an IRR of 1.3 (95% CI: 1.07-1.58; P = 0.008). In sensitivity analyses including only studies in which antibiotics were used for gastrointestinal infections, the risk of developing IBS was higher for antibiotic users (IRR: 1.71; 95% CI: 1.16-2.51; P = 0.007), with high heterogeneity ( I2 > 90%) among studies. Geographical area, criteria for IBS diagnosis and study quality were associated with estimated effects, explaining the observed heterogeneity.
Discussion:
Antibiotic use is associated with increased risk of developing IBS, especially after gastrointestinal infections. However, the significant study heterogeneity reduces the power of our results, suggesting that further high-quality research is needed to clarify this relationship.
Related Concept Videos
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:21Drugs for Treatment of Constipation-Predominant IBS